Virtu Financial’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
Other funds holding GANX
PCM
GCP
DCM
Virtu Financial's GANX Position: Q2 2026 in Review
Virtu Financial increased its Gain Therapeutics (GANX) stake by 97% in Q2 2026, buying an estimated $19K and bringing the position to 21,015 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #1237.
Virtu Financial first reported a position in GANX in Q2 2024 and has held it in 5 quarters since. The position peaked at $96K in Q3 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.
- Virtu Financial held 21,015 shares of Gain Therapeutics worth $43K as of Q2 2026.
- Virtu Financial bought 10,330 Gain Therapeutics shares in Q2 2026, an estimated $19K.
- Gain Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1237 holding.
- Virtu Financial first reported a position in Gain Therapeutics in Q2 2024 and has held it in 5 quarters since.
- Virtu Financial's Gain Therapeutics position peaked at $96K in Q3 2025.
- 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.
Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.